Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high

worldpharmanewsOctober 18, 2017

Tag: Bristol-Myers Squibb , FDA , Opdivo

PharmaSources Customer Service